Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to characterize the effect of food on the single-dose PK of TAK-659 in participants with advanced solid tumors and/or lymphomas.


Clinical Trial Description

The drug being tested in this study is called TAK-659. TAK-659 is being tested in participants with advanced solid tumors and/or lymphomas in order to determine the effect of food on the PK of single oral dose of TAK-659 tablet formulation. The study will enroll approximately 20 participants. Participants will be randomly and equally assigned (by chance, like flipping a coin) to 1 of the 2 treatment sequences following as: - TAK-659 100 mg Fasted + TAK-659 100 mg Fed - TAK-659 100 mg Fed + TAK-659 100 mg Fasted All participants will be asked to take single oral dose of TAK-659 tablet on Day 1 and Day 8 of a 15-day food effect treatment period. Upon completion of the food effect treatment period, participants can continue in the optional post food effect treatment period to receive TAK-659 100 mg, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicity, or the start of another anticancer therapy upon request by the investigator and agreement by the project clinician. This single or multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 58 weeks. Participants will visit the clinic on Day -1 and remain confined until Day 15 of food effect treatment period. Participants will make a visit to the clinic after 28 days after last dose of study drug for a follow-up assessment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03359733
Study type Interventional
Source Calithera Biosciences, Inc
Contact
Status Withdrawn
Phase Phase 1
Start date February 28, 2018
Completion date August 20, 2019

See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Completed NCT00600353 - Multi-day Doses in Prevention of Nausea and Emesis Phase 2
Completed NCT01432951 - A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma Phase 1
Completed NCT02249429 - Open-Label, Non Randomized Phase 2 Study With Safety Run-In Phase 2
Terminated NCT02440685 - A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT02732275 - DS-3201b in Participants With Lymphomas Phase 1
Completed NCT00509184 - Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma Phase 2
Recruiting NCT00619879 - Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Phase 3
Completed NCT00146055 - Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood Phase 2
Completed NCT00741871 - A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies Phase 1
Recruiting NCT04947618 - Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim
Recruiting NCT02441972 - Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics Phase 1
Completed NCT00078637 - Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma Phase 1
Completed NCT00037791 - Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Phase 3
Completed NCT01388335 - A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin Phase 1